{"nctId":"NCT01698554","briefTitle":"Bimatoprost in the Treatment of Eyelash Hypotrichosis","startDateStruct":{"date":"2012-11"},"conditions":["Idiopathic Eyelash Hypotrichosis"],"count":464,"armGroups":[{"label":"bimatoprost formulation A solution","type":"EXPERIMENTAL","interventionNames":["Drug: bimatoprost formulation A solution"]},{"label":"bimatoprost solution 0.03 %","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: bimatoprost solution 0.03 %"]},{"label":"vehicle of bimatoprost formulation A solution","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: vehicle of bimatoprost formulation A solution"]},{"label":"vehicle of bimatoprost solution 0.03 %","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: vehicle of bimatoprost solution 0.03 %"]}],"interventions":[{"name":"bimatoprost formulation A solution","otherNames":[]},{"name":"bimatoprost solution 0.03 %","otherNames":["LATISSEÂ®"]},{"name":"vehicle of bimatoprost formulation A solution","otherNames":[]},{"name":"vehicle of bimatoprost solution 0.03 %","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n-Male and female adult patients with eyelash hypotrichosis (inadequate eyelash growth).\n\nExclusion Criteria:\n\n* Damage to eyelid area (scarring) that may prevent growth of eyelashes\n* Active eye diseases (glaucoma, uveitis, eye infections, chronic blepharitis or severe dry eye)\n* Eye or eyelid surgery (including laser, refractive, intraocular filtering surgery, blepharoplasty) during the 3 months prior to screening\n* Current eyelash implants of any kind\n* Eyelash tint or dye application within 2 months of baseline\n* Eyelash extensions application within 3 months of baseline\n* Use of eyelash growth products within 6 months of baseline\n* Treatments that may affect hair growth (minoxidil, cancer chemotherapeutic agents, etc) within 6 months prior to baseline.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least a 1-Grade Increase (Improvement) From Baseline in the Investigator's Assessment of Overall Eyelash Prominence (GEA)","description":"The investigator evaluated the overall eyelash prominence in both eyes using the GEA 4-point scale: 1= minimal, 2= moderate, 3= marked and 4= very marked. A 1-grade improvement in the GEA score from Baseline indicated improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.4","spread":null},{"groupId":"OG001","value":"83.4","spread":null},{"groupId":"OG002","value":"24.0","spread":null},{"groupId":"OG003","value":"20.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Upper Eyelash Length as Measured Using Digital Image Analysis (DIA)","description":"Photographs were taken of the eyelashes and assessed using DIA. Length was measured in millimeters (mm). Data from both eyes were averaged for each participant for analysis. A positive change from Baseline indicated longer length (improvement)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.09","spread":"0.856"},{"groupId":"OG001","value":"5.97","spread":"0.789"},{"groupId":"OG002","value":"5.90","spread":"0.812"},{"groupId":"OG003","value":"6.03","spread":"0.852"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":"0.888"},{"groupId":"OG001","value":"1.62","spread":"0.955"},{"groupId":"OG002","value":"0.08","spread":"0.442"},{"groupId":"OG003","value":"0.05","spread":"0.482"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Upper Eyelash Thickness/Fullness as Measured Using DIA","description":"Photographs were taken of the eyelashes and assessed using DIA. Eyelash thickness (fullness) was measured in millimeters squared (mm\\^2). Data from both eyes were averaged for each participant for analysis. A positive change from Baseline indicated fuller eyelashes (improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":"0.400"},{"groupId":"OG001","value":"0.82","spread":"0.404"},{"groupId":"OG002","value":"0.76","spread":"0.333"},{"groupId":"OG003","value":"0.81","spread":"0.380"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"0.359"},{"groupId":"OG001","value":"0.64","spread":"0.392"},{"groupId":"OG002","value":"0.02","spread":"0.196"},{"groupId":"OG003","value":"0.03","spread":"0.237"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Upper Eyelash Intensity (Darkness) as Measured Using DIA","description":"Photographs were taken of the eyelashes and assessed using DIA. Eyelash darkness (intensity) was measured in both eyes and averaged for analysis using a scale where 0=black and 255=white. A negative change from Baseline indicated darker eyelashes (improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145.33","spread":"24.024"},{"groupId":"OG001","value":"147.39","spread":"24.934"},{"groupId":"OG002","value":"147.44","spread":"22.323"},{"groupId":"OG003","value":"145.79","spread":"26.670"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.98","spread":"15.719"},{"groupId":"OG001","value":"-24.78","spread":"16.417"},{"groupId":"OG002","value":"-2.78","spread":"10.443"},{"groupId":"OG003","value":"0.17","spread":"10.065"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Satisfied or Very Satisfied in the Patient's Assessment of Overall Eyelash Satisfaction as Measured by the Eyelash Satisfaction Questionnaire (ESQ-9)","description":"Participants rated their overall eyelash satisfaction by answering Eyelash Satisfaction Questionnaire (ESQ-9) question #3: \"Overall, how satisfied are you with your eyelashes?\" using a 5-point scale: 1= very unsatisfied (worst), 2= unsatisfied, 3= neutral, 4= satisfied or 5= very satisfied (best). The percentage of participants who rated their satisfaction as satisfied or very satisfied at Month 4 is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","spread":null},{"groupId":"OG001","value":"65.0","spread":null},{"groupId":"OG002","value":"28.0","spread":null},{"groupId":"OG003","value":"20.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":153},"commonTop":["Intraocular pressure decreased"]}}}